RSS Feed ALL

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

1 day ago

Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus...

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses

2 days ago

New 2-week reusable contact lens brings advanced ACUVUE OASYS MAX technologies to...

Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure

3 days ago

· 35+ abstracts demonstrate new findings across DARZALEX®, TECVAYLI® plus DARZALEX FASPRO®...

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

4 days ago

First presentation of pivotal Phase 3 CAPLYTA® data in adults with bipolar...

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

10 days ago

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

12 days ago

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

19 days ago

· IMAAVY is an immunoselective FcRn blocker designed to target and reduce...

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

19 days ago

· IMAAVY is an immunoselective FcRn blocker designed to target and reduce...

Johnson & Johnson Announces New Global Classification System for Surgical Outcomes

19 days ago

Peer-reviewed DISH Classification System establishes a standardized approach to reporting dehiscence, infection...

Johnson & Johnson Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence

25 days ago

Drawing on insights from leaders across healthcare, technology, policy and investment, the...

Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy

26 days ago

Introducing MONARCH™ QUEST 3, the latest software update for the MONARCH™ Platform...

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

about 1 month ago